Medicilon has been honored with the “Excellent Service Award” by its client, Eluciderm Inc., in recognition of their exceptional capabilities of Medicilon’s Elu42 IND team and their high-quality contributions to the development of the innovative therapy, Elu42.
Testimony from Eluciderm CEO, Dr. Dan Holsworth:
About ELU42
Elu42 is a small molecule applied as a topical spray for healing all open-wound types developed by Eluciderm. ELU42 has the potential to revolutionize wound care and deliver major market impact by accelerating healing and minimizing scar formation of diabetic ulcers, third-degree burns, and traumatic wounds.
About Eluciderm
Headquartered in San Diego, Eluciderm is a clinical-stage regenerative medicine company utilizing small molecules to enhance wound healing and minimize scarring after trauma. Eluciderm’s first-in-class topical small molecule platform is revolutionizing wound care, bridging science and nature to create safe, non-invasive treatments that go beyond conventional healing.
About Medicilon
From its inception in 2004, Shanghai Medicilon Inc. (stock code: 688202.SH) has been committed to providing comprehensive R&D services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space. By the end of 2024, Medicilon has provided drug development services to over 2,000 clients worldwide, and has been involved in the research and development of 520 new drugs and generic drug projects that have been approved for clinical trials with IND applications.
